Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)

NCT07161037 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Interventions

DRUG: VX-407

Sponsor

Vertex Pharmaceuticals Incorporated